Ischämischer Schlaganfall – Orale Antikoagulation in der Sekundärprävention

Zusammenfassung

Mit der Einführung der direkten Thrombin- und Faktor-Xa-Inhibitoren ergeben sich auf dem Gebiet der oralen Antikoagulanzien wirkungsvolle Alternativen zu den Vitamin-K-Antagonisten. In dieser Arbeit liegt der Schwerpunkt auf der Evidenz für den Einsatz der direkten oralen Antikoagulanzien in der Sekundärprävention des ischämischen Schlaganfalls.

Summary

The introduction of the new direct thrombin- and factor Xa-inhibitors yields effective alternatives to the Vitamin-K-antagonists. This article focuses on the evidence for the use of direct oral anticoagulants for secondary prevention after ischemic stroke.

Key words

Ischemic stroke - secondary prevention - non-valvular atrial fibrillation - irect oral anticoagulant drugs

• Literatur

• 1 Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272 Epub 2009/09/19
• 2 Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100 Epub 2010/03/20
• 3 Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125: 2298-2307 Epub 2012/04/20
• 4 Diener H-CWC. Leitlinien für Diagnostik und Therapie in der Neurologie. Herausgegeben von der Kommission “Leitlinien” der Deutschen Gesellschaft für Neurologie. Stuttgart/New York: Thieme Verlag; 09/2012
• 5 Connolly SJ, Eikelboom J, Joyner C et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817 Epub 2011/02/12
• 6 Diener HC, Eikelboom J, Connolly SJ et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012; 11: 225-231 Epub 2012/02/07
• 7 Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151 Epub 2009/09/01
• 8 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891 Epub 2011/08/13
• 9 Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992 Epub 2011/08/30
• 10 Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104 Epub 2013/11/21
• 11 Diener HC, Connolly SJ, Ezekowitz MD et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010; 9: 1157-1163 Epub 2010/11/10
• 12 Hankey GJ, Patel MR, Stevens SR et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012; 11: 315-322 Epub 2012/03/10
• 13 Easton JD, Lopes RD, Bahit MC et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.. Lancet Neurol 2012; 11: 503-511 Epub 2012/05/11
• 14 Rasmussen LH, Larsen TB, Graungaard T et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ 2012; 345: e7097-e7097 Epub 2012/11/07
• 15 Heidbuchel H, Verhamme P, Alings M et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013; 34: 2094-2106 Epub 2013/04/30